Melphalan
- Generic Name
- Melphalan
- Brand Names
- Alkeran, Evomela, Phelinun, Pepaxti
- Drug Type
- Small Molecule
- Chemical Formula
- C13H18Cl2N2O2
- CAS Number
- 148-82-3
- Unique Ingredient Identifier
- Q41OR9510P
- Background
Melphalan is a nitrogen mustard or bischloroethylamine type alkylating agent. It was first synthesized in the early 1950s by substituting L-phenylalanine for the methyl group on nitrogen mustard. Melphalan is used in the treatment of multiple myeloma and ovarian carcinoma. It is also used for high-conditioning before hematopoietic stem cell transplant. It is...
- Indication
Melphalan is indicated for use as a high-dose conditioning treatment prior to hematopoietic stem cell transplantation in patients with multiple myeloma. It is also indicated for the palliative treatment of multiple myeloma and for the palliation of non-resectable epithelial carcinoma of the ovary.
...
- Associated Conditions
- Multiple Myeloma (MM), Unresectable Liver Metastasis, Unresectable Ovarian Cancer (Epithelial)
- Associated Therapies
- Conditioning regimens for allogeneic stem cell transplantation therapy
Reduce Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed Multiple Myeloma
- First Posted Date
- 2019-12-19
- Last Posted Date
- 2023-09-28
- Lead Sponsor
- Srinivas Devarakonda
- Target Recruit Count
- 1
- Registration Number
- NCT04205240
- Locations
- 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies
- Conditions
- Interventions
- First Posted Date
- 2019-12-09
- Last Posted Date
- 2024-12-13
- Target Recruit Count
- 37
- Registration Number
- NCT04191187
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
SHARON: A Clinical Trial for Metastatic Cancer With a BRCA or PALB2 Mutation Using Chemotherapy and Patients' Own Stem Cells
- Conditions
- Interventions
- First Posted Date
- 2019-11-04
- Last Posted Date
- 2024-06-26
- Lead Sponsor
- General Oncology, Inc.
- Target Recruit Count
- 10
- Registration Number
- NCT04150042
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
Giving Chemotherapy for a Shortened Amount of Time Before a Stem Cell Transplantation
- First Posted Date
- 2019-09-23
- Last Posted Date
- 2024-06-27
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 39
- Registration Number
- NCT04098393
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Bendamustine With or Without Cyclophosphamide in Preventing GVHD in Patients Undergoing Stem Cell Transplant
- Conditions
- Interventions
- First Posted Date
- 2019-07-17
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 25
- Registration Number
- NCT04022239
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Early Human Leukocyte Antigen (HLA) Matched Sibling Hematopoietic Stem Cell Transplantation
- Conditions
- Interventions
- First Posted Date
- 2019-07-15
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- Emory University
- Target Recruit Count
- 43
- Registration Number
- NCT04018937
- Locations
- 🇺🇸
Children's Hospital of Alabama, Birmingham, Alabama, United States
🇺🇸Phoenix Children's, Phoenix, Arizona, United States
🇺🇸Yale University, Yale Cancer Center, New Haven, Connecticut, United States
Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Leukemia or Lymphoma Undergoing Stem Cell Transplantation
- Conditions
- Interventions
- First Posted Date
- 2019-02-27
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 44
- Registration Number
- NCT03856216
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Allogeneic Hematopoietic Cell Transplantation From HLA-matched Donor After Flu-Mel-PTCy Versus Flu-Mel-ATG Reduced-intensity Conditioning
- Conditions
- Interventions
- First Posted Date
- 2019-02-25
- Last Posted Date
- 2022-10-12
- Lead Sponsor
- University of Liege
- Target Recruit Count
- 114
- Registration Number
- NCT03852407
- Locations
- 🇧🇪
CHU UCL Namur Godinne, Yvoir, Belgium
🇧🇪UZ Gent, Gent, Belgium
🇧🇪UCL St Luc, Brussels, Belgium
TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies
- Conditions
- Interventions
- First Posted Date
- 2019-02-21
- Last Posted Date
- 2024-08-19
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 140
- Registration Number
- NCT03849651
- Locations
- 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States
STUDY COMPARING TWO STANDARD TREATMENTS IN AUTOLOGOUS STEM CELL TRANSPLANTATION INELIGIBLE POPULATION AFFECTED BY MULTIPLE MYELOMA
- Conditions
- Interventions
- First Posted Date
- 2019-02-04
- Last Posted Date
- 2024-05-08
- Lead Sponsor
- University of Turin, Italy
- Target Recruit Count
- 450
- Registration Number
- NCT03829371
- Locations
- 🇮🇹
Dipartimento di Biotecnologie Molecolari e Scienze per la Salute, Torino, TO, Italy
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.